Hercules Capital Archives

Hercules Capital Provides $25MM Credit Facility to Locus Biosciences

Locus Biosciences, a clinical-stage biotechnology company developing a new class of precision engineered bacteriophage treatments for bacterial and inflammatory diseases, entered a credit facility of up to $25 million with Hercules Capital.

October 20, 2021 Bryan Jadot | Hercules Capital | Locus Biosciences | Paul Garofolo Ian Koplin

Hercules Capital Expands Term Loan Facility to $300MM for Axsome Therapeutics

Hercules Capital amended the existing term loan facility agreement it has with Axsome Therapeutics to increase the size of the facility to $300 million and the amount immediately available upon FDA approval of AXS-05 for major depressive disorder to $100 million at the company’s option.

October 19, 2021 Axsome Therapeutics | Hercules Capital | Herriot Tabuteau | Michael Dutra Ian Koplin

Hercules Capital Provides $30MM Debt Facility to Eloxx Pharmaceuticals

Eloxx Pharmaceuticals entered into a debt facility of up to $30 million with Hercules Capital, a specialty financing lender for life science and technology companies. Eloxx has drawn the initial tranche of $12.5 million and used the proceeds to repay in full amounts outstanding under its existing debt facility.

October 6, 2021 Eloxx Pharmaceuticals | Hercules Capital | Janice Bourque | Sumit Aggarwal Ian Koplin

Hercules Capital Provides $235MM to Corium, Surpasses $1.5B in Commitments in 2021

Corium, a commercial-stage biopharmaceutical company, closed on a $235 million term loan agreement with Hercules Capital. Hercules Capital also reported it has originated more than $1.5 billion year to date in annual total gross debt and equity commitments in 2021, breaking its previous one-year record.

Hercules Capital Provides $200MM Term Loan to Phantom Pharmaceuticals

Phathom Pharmaceuticals, a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, obtained a $200 million term loan facility from Hercules Capital.

Hercules Capital Provides $50MM Debt Facility to Better Therapeutics

Better Therapeutics, a prescription digital therapeutics company developing cognitive behavioral therapy to address the root causes of cardiometabolic diseases, secured a loan facility for up to $50 million from Hercules Capital.

August 26, 2021 Better Therapeutics | Cristy Barnes | Hercules Capital | Kevin Appelbaum | Mark Heinen Ian Koplin

Hercules Capital Surpasses $1B Milestone in Annual Debt & Equity Commitments

Hercules Capital, a specialty financing provider to venture, growth and established stage companies backed by venture capital and select private equity firms, has originated more than $1 billion year-to-date in annual total debt and equity commitments for the fourth consecutive year.

August 3, 2021 Hercules Capital | Scott Bluestein Ian Koplin

Hercules Capital Provides $30MM Debt Facility to HiberCell

HiberCell, a biotechnology company developing therapeutics for the prevention of cancer relapse and metastasis, closed on a $30 million debt facility with Hercules Capital. In addition, HiberCell completed a Series B financing round for gross proceeds of $67.4 million.

Hercules Capital and SVB Provide $60MM Term Loan to SCYNEXIS

SCYNEXIS secured a $60 million term loan facility with Hercules Capital and Silicon Valley Bank. The capital strengthens SCYNEXIS’ balance sheet ahead of the anticipated commercial launch of Brexafemme, an oral antifungal product for the treatment of vaginal yeast infections.

Hercules Capital and SVB Provide $75MM Loan Facility to Geron

Hercules Capital and Silicon Valley Bank provided a loan facility of up to $75 million for Geron, supporting the company with access to non-dilutive financial resources to support its imetelstat development program.

October 2, 2020 Geron | Hercules Capital | Imetelstat | Olivia K. Bloom | Silicon Valley Bank Phil Neuffer

Tag Archives: Hercules Capital